Asco 2015 – A phase II and biomarker study of cabozantinib (XL-184) in
- This topic has 0 replies, 1 voice, and was last updated 9 years, 2 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
A phase II and biomarker study of cabozantinib (XL-184) in patients (pts) with advanced cholangiocarcinoma (CCA).
http://abstracts.asco.org/156/AbstView_156_152986.html
Viewing 1 post (of 1 total)
- The forum ‘New Developments’ is closed to new topics and replies.